Photo courtesy Medline Inc.<br />Medline's Brian Tompkins, left, director of marketing, Proxima Division and David Greenberg, executive vice president of strategy, were honored at the NASDAQ stock exchange in New York City &nbsp;in celebration of winning the Chicago Innovation Award for its new BioMask, the first FDA-cleared antiviral medical face mask that is shown to inactivate flu viruses.
Photo courtesy Medline Inc.
Medline's Brian Tompkins, left, director of marketing, Proxima Division and David Greenberg, executive vice president of strategy, were honored at the NASDAQ stock exchange in New York City  in celebration of winning the Chicago Innovation Award for its new BioMask, the first FDA-cleared antiviral medical face mask that is shown to inactivate flu viruses.
MUNDELEIN - Medline Industries, Inc. rang the closing bell at the NASDAQ Stock Market in New York City Feb. 25 in celebration of winning the Chicago Innovation Award for its new BioMask, the first FDA-cleared antiviral medical face mask that is shown to inactivate flu viruses.
Organized by the Chicago Innovation Awards, the event included representatives from Medline and the other winners of the Chicago Innovation awards.
BioMask is the first FDA-cleared antiviral medical face mask that inactivates 99.99 percent of laboratory-tested flu viruses on five minutes contact, including imminent pandemic and seasonal strains of influenza viruses, such as H1N1, Avian flu, Swine flu and H3N2, this year's dominant flu strain in the United States. Traditional facemasks act only as an air filter and do nothing to neutralize the harmful germs that remain active on the mask itself.
"We are especially proud to receive this innovation award as BioMask has the potential to help protect health care workers, patients and vulnerable groups such as children, the elderly, pregnant women and people with compromised immunities," said David Greenberg, Medline's executive vice president of strategy. Greenberg represented Medline in the NASDAQ closing ceremony.
The benefit of the BioMask is that it can provide protection from cross contamination. The outer facing of the mask is frequently touched by the user, who then touches other things or people. Since BioMask inactivates 99.99 percent of the tested flu viruses on five minutes contact, the risk of spreading the virus is greatly reduced.
""We congratulate Medline for winning the Chicago Innovation Awards, and applaud their commitment to innovation," said Dan Miller, co-founder of the Chicago Innovation Awards.